Published on

Clinical Toxicology — Pyrrolizidine Alkaloids

1. Overview

Pyrrolizidine alkaloids (PAs) are naturally occurring compounds produced by numerous plant species. Certain PAs can cause severe liver injury, particularly hepatic sinusoidal obstruction syndrome (HSOS), formerly known as hepatic veno-occlusive disease.

Human exposure occurs mainly through herbal medicines, traditional remedies, contaminated grains, herbal teas, and certain other foods.

Most poisonings result from repeated consumption over days, weeks, or months. However, highly concentrated preparations can cause serious injury after shorter exposures.

The principal clinical features are abdominal discomfort, hepatomegaly, fluid retention, ascites, and portal hypertension. Jaundice may occur but is not always prominent.

Severe cases can progress to acute liver failure, kidney dysfunction, respiratory complications, and death.

There is no established specific antidote. Management begins with eliminating exposure and providing supportive treatment. Selected patients with PA-induced HSOS may benefit from specialist-directed anticoagulation or transjugular intrahepatic portosystemic shunt (TIPS).

2. Chemical classification

Pyrrolizidine alkaloids are a chemically diverse group of plant secondary metabolites.

More than 600 PA structures and related compounds have been described.

They are present or predicted to occur in thousands of plant species, although not all species or alkaloids have the same toxicologic significance.

1,2-Unsaturated pyrrolizidine alkaloids

The principal toxicologic concern involves 1,2-unsaturated pyrrolizidine alkaloids, which contain a double bond within the necine base structure.

Following metabolic activation, these compounds can form reactive pyrrolic metabolites capable of damaging proteins and DNA.

Examples include retrorsine, senecionine, seneciphylline, riddelliine, and monocrotaline.

Saturated pyrrolizidine alkaloids

Not all PAs undergo the same metabolic activation.

Many saturated compounds have substantially lower hepatotoxic or genotoxic potential.

N-oxides

Pyrrolizidine alkaloid N-oxides may also contribute to toxicity because they can be converted to corresponding tertiary alkaloids.

The presence of a pyrrolizidine structure alone does not establish that a particular compound is highly hepatotoxic.

3. Important botanical sources

Comfrey

Botanical genus: Symphytum.

Common comfrey, Symphytum officinale, contains pyrrolizidine alkaloids capable of producing HSOS.

Comfrey has historically been taken orally as teas, capsules, or powders for gastrointestinal conditions, injuries, and inflammatory complaints.

Oral comfrey products have caused severe liver injury.

Topical comfrey preparations are available in some countries, but their safety depends on formulation, PA content, skin integrity, and regulatory controls.

Oral consumption should be avoided.

Groundsel and ragwort

Botanical groups: Senecio and Jacobaea species.

These plants contain various hepatotoxic PAs.

They are important causes of livestock poisoning and can contaminate human food crops.

Heliotrope

Botanical genus: Heliotropium.

Certain species contain hepatotoxic alkaloids.

Contamination of harvested grains with heliotrope seeds has contributed to outbreaks of liver disease.

Coltsfoot

Botanical name: Tussilago farfara.

Coltsfoot has been used in traditional respiratory remedies.

Some varieties contain potentially harmful PAs.

Its name or traditional use should not be taken as evidence of safety.

Other relevant plants

Additional sources include certain Echium, Crotalaria, Borago, and Gynura species.

A particularly important cause of PA-associated HSOS in China has been traditional herbal preparations containing Gynura segetum, often referred to by the name Tusanqi.

Important identification warning

Different plants may share the name Sanqi or Tusanqi.

Not all such products contain the same botanical ingredients.

Accurate species identification is essential.

4. Sources of human exposure

Herbal medicines

Herbal teas, capsules, powders, and concentrated root preparations are important sources of clinically significant poisoning.

The quantity of alkaloid in these products may vary enormously.

Traditional preparation methods do not necessarily eliminate toxicity.

Contaminated grains

Weeds containing PAs can contaminate grain crops during harvesting.

When contaminated grains are milled and consumed repeatedly, communities may experience outbreaks of hepatic injury.

Tea and herbal infusions

Certain teas contain PAs because of the ingredients themselves or contamination with PA-producing plants.

The public-health concern is greatest with repeated consumption of products containing elevated PA concentrations.

Honey

PAs can enter honey when bees collect nectar or pollen from PA-producing plants.

However, ordinary honey consumption should not be equated with clinically established acute PA poisoning.

Food-safety authorities primarily identify concern about long-term dietary exposure and possible genotoxic or carcinogenic effects, particularly among high consumers.

Food supplements

Botanical dietary supplements may contain PA-producing plants or inadvertently contaminated ingredients.

Products may not reliably disclose their PA content.

Pregnancy and infant exposure

Maternal ingestion of PA-containing preparations can expose the developing fetus.

Severe fetal and neonatal injury has been reported.

Herbal teas marketed for infants or maternal use should not be assumed safe without adequate ingredient identification and quality control.

5. Toxic dose

No single oral dose reliably predicts poisoning.

Severity depends on:

  • Specific PA structure.
  • Concentration of hepatotoxic PAs.
  • Cumulative exposure.
  • Duration of consumption.
  • Metabolic activation.
  • Age and body weight.
  • Nutritional status.
  • Existing liver disease.
  • Other potentially hepatotoxic exposures.

Historical case reports provide estimated toxic doses, but these values should not be used as universal clinical thresholds.

Acute versus chronic exposure

A highly concentrated product may cause significant injury over days or weeks.

Repeated lower-level ingestion can produce progressive hepatic injury over months.

Children

Infants and young children may be particularly vulnerable because of their smaller body mass and developmental physiology.

Food-safety interpretation

Dietary exposure limits and carcinogenic risk assessments are not equivalent to clinical thresholds for acute liver failure.


6. Pathophysiology

Hepatic metabolic activation

Certain 1,2-unsaturated PAs undergo metabolism through hepatic cytochrome P450 enzymes.

This produces reactive dehydropyrrolizidine metabolites, commonly called pyrrolic metabolites.

Cellular injury

The reactive metabolites can bind to cellular proteins and nucleic acids.

Protein adduct formation disrupts normal cellular function.

DNA adduct formation contributes to genotoxic potential.

Sinusoidal endothelial injury

The hepatic sinusoidal endothelial cells are especially vulnerable.

Injury causes swelling, disruption, and detachment of endothelial cells.

Cellular debris and other changes obstruct sinusoidal blood flow.

Portal hypertension

Obstruction increases resistance to blood flow through the liver.

The resulting hepatic congestion can produce hepatomegaly, ascites, and portal hypertension.

Progressive disease

Persistent injury may result in fibrosis and structural changes involving terminal hepatic venules.

This can produce chronic liver disease even after exposure ceases.

Carcinogenicity

Several 1,2-unsaturated PAs have demonstrated carcinogenic activity in experimental animals.

Human carcinogenic risk is biologically plausible, and regulatory authorities consider these compounds potentially genotoxic carcinogens.

However, the magnitude of human cancer risk from specific dietary exposures remains uncertain.

7. Clinical manifestations

The most characteristic presentation is hepatic sinusoidal obstruction syndrome.

Early findings

Symptoms may include fatigue, anorexia, nausea, and abdominal discomfort.

Patients may notice progressive abdominal swelling or unexplained weight gain.

Hepatic findings

Important manifestations include:

  • Painful hepatomegaly.
  • Right-upper-quadrant discomfort.
  • Ascites.
  • Rapid fluid retention.
  • Increased body weight.
  • Jaundice in some patients.

Portal hypertension

Portal hypertension may cause worsening ascites, splenic enlargement, and eventually gastrointestinal bleeding from varices.

Laboratory abnormalities

Serum bilirubin and aminotransferases may be elevated.

However, some patients with clinically important sinusoidal obstruction have relatively modest aminotransferase elevations.

Normal or mildly abnormal liver enzyme values do not reliably exclude serious HSOS.

Acute liver failure

Severe cases may develop coagulopathy, encephalopathy, hypoglycemia, and multiorgan dysfunction.

Kidney injury

Acute kidney injury may occur during severe illness.

Potential mechanisms include reduced effective circulation, severe hepatic dysfunction, and other systemic complications.

Respiratory complications

Marked ascites and fluid retention may impair ventilation.

Pleural effusions or pulmonary edema can occur in severe disease.

Certain PAs, particularly monocrotaline, are associated with pulmonary vascular injury in experimental research. Human pulmonary hypertension from PA exposure is much less well characterized than hepatic HSOS.

8. Diagnosis

Diagnosis requires integration of the exposure history, clinical presentation, imaging, and exclusion of alternative conditions.

Exposure history

Ask specifically about:

  • Herbal teas.
  • Traditional Chinese or other traditional medicines.
  • Comfrey products.
  • Homemade botanical remedies.
  • Dietary supplements.
  • Unusual grain products.
  • Multiple affected household members.

Determine the brand or botanical identity, dose, duration, preparation method, and date of last use.

Retain the product packaging or a sample for possible analysis.

Clinical assessment

Assess weight change, abdominal distension, liver tenderness, fluid status, jaundice, and signs of portal hypertension.

Blood tests

Initial investigations should include:

  • Complete blood count.
  • AST and ALT.
  • Alkaline phosphatase.
  • Total and direct bilirubin.
  • Albumin.
  • PT/INR.
  • Electrolytes.
  • Creatinine.
  • Blood glucose.

Repeat testing according to disease severity and clinical progression.

Imaging

Doppler ultrasonography is often an appropriate initial study.

It can identify ascites, hepatomegaly, altered hepatic blood flow, and evidence of portal hypertension.

Contrast-enhanced CT or MRI may demonstrate:

  • Heterogeneous or patchy liver enhancement.
  • Hepatomegaly.
  • Ascites.
  • Narrowing or poor visualization of hepatic veins.
  • Changes associated with hepatic congestion.

These findings support HSOS but must be interpreted with the clinical picture.

Nanjing diagnostic criteria

The Nanjing criteria were developed for PA-induced HSOS.

They incorporate a credible history of PA exposure, characteristic symptoms and signs, laboratory abnormalities, and supportive imaging or pathologic findings.

They have undergone retrospective clinical validation.

However, no diagnostic tool is perfect, and the criteria must be applied with consideration of competing hepatic vascular diseases.

Liver biopsy

Histology can demonstrate sinusoidal congestion, endothelial injury, centrilobular injury, and venular fibrosis.

Routine liver biopsy is not necessary in every suspected case.

Ascites, coagulopathy, and other complications may make biopsy hazardous.

When tissue confirmation is essential, a transjugular approach may be safer in selected patients.


9. Specialized diagnostic testing

Pyrrole-protein adducts

Reactive metabolites of PAs can bind circulating proteins, producing pyrrole-protein adducts (PPAs).

Specialized liquid chromatography–mass spectrometry methods can detect these compounds.

Clinical value

Published studies demonstrate that PPA testing can support confirmation of PA-associated liver injury and help distinguish it from certain other causes.

Limitations

These tests are not routinely available in most emergency or hospital laboratories.

Their performance depends on analytical methods, timing, and the population studied.

A negative result should not automatically override strong clinical evidence.

Herbal product analysis

Specialized laboratories may analyze retained herbal preparations for specific PAs.

Product analysis can be useful for diagnosis and public-health investigation.


10. Differential diagnosis

The clinical findings of HSOS overlap with several important disorders.

Hepatic vascular disease

Budd–Chiari syndrome is a particularly important alternative diagnosis.

Both conditions can produce hepatomegaly, ascites, abdominal pain, and abnormal hepatic enhancement.

However, Budd–Chiari syndrome involves obstruction of hepatic venous outflow at larger hepatic veins or the inferior vena cava, whereas PA-associated HSOS primarily involves sinusoidal and small venular injury.

Other conditions

Additional differential diagnoses include:

  • Cirrhosis and decompensated chronic liver disease.
  • Acute viral hepatitis.
  • Autoimmune hepatitis.
  • Acetaminophen poisoning.
  • Other herbal or drug-induced liver injury.
  • Congestive hepatopathy.
  • Portal vein thrombosis.
  • Liver malignancy.
  • HSOS associated with chemotherapy or hematopoietic stem-cell transplantation.

The patient’s medication history, imaging findings, and exposure history help distinguish these conditions.


11. Treatment

General principles

There is no established PA-specific antidote.

Treatment has three priorities:

  1. Immediately stop exposure.
  2. Manage hepatic congestion, fluid retention, and organ complications.
  3. Identify patients who require specialist interventions.

Remove the source

Discontinue all suspected PA-containing herbal medicines or supplements.

Do not allow continued exposure while awaiting product analysis.

Assess whether other household members have consumed the same preparation.

Gastrointestinal decontamination

Because poisoning usually follows repeated exposure and presents after a delay, gastrointestinal decontamination rarely has a role.

Do not induce vomiting.

Routine gastric lavage is not recommended.

Activated charcoal might be considered after an unusually large, clearly recent ingestion of a concentrated product, but benefit is unproven and the decision requires individual toxicology assessment.

Fluid management

Manage fluid status carefully.

Excessive intravenous fluid administration can worsen ascites and hepatic congestion.

Patients with clinically significant ascites may require sodium restriction, diuretics, and therapeutic paracentesis according to standard liver-disease management.

Avoid dehydration and hypotension, which can worsen kidney function.

Nutritional support

Ensure adequate nutrition and assess for malnutrition.

Avoid alcohol and unnecessary hepatotoxic medications.

Encephalopathy

Hepatic encephalopathy and acute liver failure require urgent hospital treatment.

Portal hypertensive bleeding

Variceal hemorrhage requires emergency management using established portal-hypertension protocols.


12. Anticoagulation

This is an important area where contemporary literature differs from older references.

Some studies and Chinese expert consensus recommendations support anticoagulation for selected patients with acute or subacute PA-induced HSOS.

Low-molecular-weight heparin has been used, sometimes followed by an oral anticoagulant.

Evidence limitations

Much of the evidence comes from observational studies and specialist clinical experience rather than large randomized controlled trials.

The potential benefit must be balanced against bleeding risks.

Clinical recommendation

**Anticoagulation should


Image description
0 Comments